In a 12-minute explainer, psychiatrist Dr. Tracey Marks maps a clinical psilocybin dose onto three brain changes — a quieter default mode network, more cross-talk between regions, and a weeks-long plasticity window — then onto Compass Pathways’ COMP360 program for treatment-resistant depression. The molecule is not a take-home pill. Screening, a supervised container, and integration are part of the treatment. Marks recorded this in October 2025, after COMP005 met its primary endpoint; COMP006’s 26-week data arrived in July 2026.
Watch the explainer
Dr. Tracey Marks, psychiatrist, on how a clinical psilocybin dose changes brain networks and where COMP360 stood as of October 2025. Watch on YouTube.
What Marks actually said
Marks’s claim is mechanistic, not mystical: a measured clinical dose can temporarily loosen rigid brain-network patterns, and that window is only useful if therapy, screening, and follow-up are in the room.
The 12-minute video is a psychiatrist’s tour of two questions most study abstracts skip: what a clinical psilocybin dose does to brain networks, and how close that science is to becoming a medicine you can actually get.
Marks starts with treatment-resistant depression — the large group of people who do not get enough benefit from conventional antidepressants — then walks the cascade: psilocybin converts to psilocin, psilocin hits serotonin 5-HT2A receptors, and those receptors set off a change in how brain regions talk to each other. The rest of the video is that cascade in plain language, plus a regulatory snapshot.
She is explicit about the product she is describing. When she says “dose,” she does not mean a vape-shop microdose or a bag of dried mushrooms. She means synthetically produced psilocybin made for medical use, because precise milligrams and quality control are what FDA-track trials require.
Source video: https://youtu.be/5bTq3j6zPsw
Marks’s cited reference on ego dissolution: Letheby & Gerrans, Neuroscience of Consciousness (2017) — https://doi.org/10.1093/nc/nix016
The default mode network goes quiet
Marks’s first mechanism is a quieter default mode network — the inner narrator that, in depression and anxiety, often loops the same negative story. Psilocybin dampens that loop so other brain regions can talk.
The default mode network (DMN) is the set of regions that light up when you are not on a task: daydreaming, self-talk, replaying the past. In depression and anxiety it can get stuck. Marks’s metaphor is a narrator that will not stop talking, and worse, keeps telling the same negative stories. That is rumination.
Psilocybin, in her telling, turns the volume down. With the DMN less dominant, two other things show up in the imaging literature she is summarizing:
- More cross-talk. Regions that rarely exchange information start to. Marks compares a well-conducted orchestra to a few minutes of improvisation — not random noise, but a break from the usual score.
- Desynchronization as a feature. The temporary loss of the usual harmony is what lets the brain leave a rigid pattern and try a new one.
This is the same network we define in the glossary: /glossary/default-mode-network. The receptor that starts the cascade is here: /glossary/5-ht2a-receptor. For the full metabolism path (psilocybin → psilocin), see /magic-mushrooms/how-they-work.
A 2026 Nature Communications study in healthy volunteers later measured the acute brain-state change more directly: EEG entropy rose during a 25mg session, and white-matter microstructure still looked different a month later. Marks’s explainer is the clinical-language version of that claim. Read our summary: /blog/industry-news/single-psilocybin-dose-brain-changes-month
The “fresh snow” window is the treatment, not the afterthought
Marks’s most useful image is a snowy hill with deep sled tracks. Psilocybin is a fresh layer of snow. For several weeks the brain is more plastic — which is why preparation and integration are part of the dose, not extras.
Once the old ruts are covered, you can carve a new line down the hill. Marks calls this a phase of enhanced plasticity, sometimes described as critical-period reopening: the adult brain briefly behaves a little more like a child’s in how quickly it can learn.
The window is measured in weeks, not hours. Neural circuits can reorganize more easily after the session, which is why guided psychological support in that period is not a wellness add-on. It is the use of the biology. Marks’s contrast with traditional antidepressants is speed and breadth: SSRIs also touch neuroplasticity, but psilocybin appears to act faster and across a wider set of connections, including prefrontal cortex and hippocampus — decision-making and emotional memory.
That is also why a “heroic” or clinical dose without a container is a different intervention than the one in these trials. Johns Hopkins-style high-dose work is the other half of this picture: /blog/industry-news/heroic-dose-psilocybin-johns-hopkins
Marks’s milligrams are pharmaceutical psilocybin. Dried mushroom potency is a lottery. If you cannot verify the milligrams, you do not have a COMP360-style dose. You have an estimate. See /dosage and /blog/industry-news/psilocybin-dose-dependent-effects
Ego dissolution, then the unglamorous part: integration
The subjective shift Marks describes — connection, a quieter “I,” less fear when approaching old material — is the acute state. Lasting change tracks how much support someone gets in the days and weeks after.
People often report a deep sense of connection, not only to other people but to life as a whole. Scientists call the self-softening ego dissolution: the rigid inner narrator quiets, and problems look different. With the DMN on mute and emotional centers more engaged, difficult memories can be approached with less fear and more flexibility. Glossary: /glossary/ego-dissolution
Marks’s emphasis is what happens next. Integration can last days to weeks while the brain is still more plastic. Several studies, she says, show that the amount of support in that period is directly proportional to how much lasting change people get. Clinical protocols now treat preparation and post-session integration as required, not optional. Without guidance, some of the neural and psychological benefit may fade — or feel overwhelming.
That matches the afterglow window we use in harm-reduction guides: /glossary/afterglow and /guides/psychedelic-integration-workbook. Practical preparation: /guides/trip-preparation and /guides/psilocybin-therapy
From lab to pharmacy: what COMP360 had done by the video — and since
Marks correctly reported Compass Pathways’ June 2025 COMP005 win: a single 25mg COMP360 dose beat placebo on depression severity with no unexpected safety signal. The second trial’s 26-week data, which she said were still coming, were announced in July 2026.
As of the October 2025 recording, the lead FDA-track program was Compass Pathways’ synthetic psilocybin, COMP360. In June 2025 Compass announced that the first Phase 3 trial (COMP005) met its primary endpoint: a single 25mg dose produced a statistically significant and clinically meaningful reduction in depression symptom severity versus placebo, with no unexpected safety issues. Marks is careful: important results, and only the beginning. A second, larger trial was still running, with 26-week results expected in 2026. The FDA would look at the full package before any approval decision.
She also names other groups running related work — Usona Institute and Beckley Psytech — on major depression and PTSD, plus a wider push into addiction, anxiety, and end-of-life distress. The hurdles she lists are the ones the field actually has: some trials show modest effect sizes; there are not enough trained therapists; set and setting change outcomes; a take-home pill is not the model.
What happened after the video. On July 7, 2026, Compass reported 26-week (Part B) data from COMP006, the second Phase 3 study, in nearly 600 people with highly chronic treatment-resistant depression. In the 25mg arm, 39% reached a clinically meaningful MADRS reduction (≥25%) by week 6 after two fixed doses and, on average, held that benefit through week 26 — compared with 25% in COMP005 after a single dose. Compass described a generally well-tolerated profile, with most adverse events transient and clustered on dosing day. The company has said a rolling NDA is underway, with final submission aimed at Q4 2026, and — subject to FDA approval and DEA rescheduling — a possible launch in the first half of 2027. That is a company timeline, not an approval.
COMP005 announcement (June 23, 2025): https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/
COMP006 26-week data (July 7, 2026): https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Six-Month-Data-from-Second-Phase-3-Trial-Confirming-Rapid-and-Durable-Profile/default.aspx
Condition evidence: /conditions/depression and /for/treatment-resistant-depression. Field snapshot from earlier in 2026: /blog/industry-news/psychedelic-therapy-trends-2026
Marks also flags early work on biomarkers (who is most likely to benefit) and non-hallucinogenic analogs. Those are research directions, not products you can get.
Oregon and Colorado are not the same as COMP360
State-licensed services use natural mushrooms and individually chosen doses inside a regulated center. COMP360 uses a fixed high-purity 25mg synthetic capsule in a trial protocol. Do not copy one onto the other.
Marks’s access map is the one we use too. Federally, approval is still pending. Some states did not wait. Oregon launched regulated psilocybin services in 2023. Colorado licenses healing centers for supervised sessions. Both are tightly regulated service-center models — not retail, not unsupervised consumption.
The product is different. State programs use natural mushrooms, with flexible, individually chosen doses. They do not map cleanly onto the fixed 25mg synthetic doses in Compass and Usona trials. That is not a knock on either model. It is why you cannot treat an Oregon session as “the Phase 3 protocol” or a COMP360 capsule as “what the service center gave me.”
Legal status: /legal-status/oregon and /legal-status/colorado. Cost and what a supervised session actually includes: /blog/industry-news/psilocybin-therapy-cost
Who this is not for — and why “reboot” can cut both ways
The same plasticity window that can loosen rumination can also encode a bad experience. People with personal or family psychosis or bipolar history are generally excluded from trials. Heart conditions and drug interactions are additional cautions.
Marks’s close is the part a highlight reel usually drops.
The most compelling evidence she cites is for severe treatment-resistant depression, inside trials with careful screening and professional oversight. It is not a miracle cure and not a replacement for existing care — “at least not yet.”
Not everyone is a candidate. Personal or family history of psychosis or bipolar disorder is a standard exclusion. Heart conditions and interactions with certain medications are reasons for caution. One major reason self-medicating is dangerous, in her words, is the “mind-brain destabilization window”: when networks are flexible, negative experiences can leave a mark too. Integration, structure, and a safe room are how you use that window instead of getting used by it.
Net: psilocybin will not just be a pill you take home. It is a process — guidance before, during, and after. Legal access for most people is still clinical trials or state-approved service centers. Underground therapy exists and carries more risk and less oversight.
If you have a personal or family history of psychotic illness or bipolar disorder, a high-dose session is the wrong experiment. Trial protocols exclude those histories for a reason.
PsyBear takeaways
Treat Marks’s “brain reboot” as a supervised clinical intervention with a weeks-long integration tail. The neuroscience is the easy story. Screening, a real container, and not confusing state mushrooms with a 25mg synthetic capsule are the work.
Here is what we are taking from Marks’s explainer — and what we are not.
1. The trip is part of the mechanism. A quieter DMN, more cross-talk, and a plasticity window are not side effects you grit through. They are why a single session can move symptoms for weeks. They are also why a chaotic setting can move them the wrong way.
2. Milligrams in a trial are not grams in a bag. 25mg COMP360 is weighed synthetic psilocybin. Oregon and Colorado sessions use natural mushrooms at facilitator-chosen doses. Do not mix the labels.
3. Integration is proportional to the outcome. Marks’s strongest clinical sentence is not about receptors. It is that support after the session tracks lasting change. Budget the weeks after the way the protocols do: /guides/psychedelic-integration-workbook
4. “Reboot” is a metaphor, not a factory reset. Neuroplasticity can encode insight or panic. Screening for psychosis-spectrum risk is not optional. See /guides/safe-trip
5. Phase 3 is not FDA approval. COMP005 (June 2025) and COMP006 26-week data (July 2026) are the strongest psilocybin depression package to date. Compass is talking NDA timing. Until the FDA and DEA move, this remains investigational at the federal level.
6. State programs are real access, with a different product. If you want a legal, supervised path today, start with /legal-status/oregon, /legal-status/colorado, and /guides/psilocybin-therapy. If you are anywhere else, prioritize trials and legal retreats over improvising a “single dose” at home.
7. Non-hallucinogenic analogs are a headline, not a treatment. Early research is worth watching. It is not a reason to wait for a side-effect-free mushroom or to skip the container we already know how to run.
Psilocybin remains a Schedule I substance under U.S. federal law outside licensed state programs and approved trials. This article is education and commentary on a public explainer, not medical advice and not an instruction to take a clinical dose.
Key Takeaways
In a 12-minute explainer, psychiatrist Dr. Tracey Marks maps a clinical psilocybin dose onto three brain changes — a quieter default mode network, more cross-talk between regions, and a weeks-long plasticity window — then onto Compass Pathways’ COMP360 program for treatment-resistant depression. The molecule is not a take-home pill. Screening, a supervised container, and integration are part of the treatment. Marks recorded this in October 2025, after COMP005 met its primary endpoint; COMP006’s 26-week data arrived in July 2026.
FAQ
- How does psilocybin change the brain?
- In Dr. Tracey Marks’s explainer, ingested psilocybin converts to psilocin, which binds serotonin 5-HT2A receptors. That activity is associated with a quieter default mode network, more communication between brain regions that usually stay segregated, and a weeks-long window of enhanced neuroplasticity. Those changes are the proposed basis for the antidepressant effects seen in clinical trials — not a guarantee of benefit for every person.
- What is the default mode network in psilocybin research?
- The default mode network is the set of brain regions active during self-referential thought, daydreaming, and rumination. Marks describes it as an inner narrator that, in depression and anxiety, can get stuck on the same negative stories. Psilocybin appears to dampen that activity so other networks can interact more freely.
- Is COMP360 FDA-approved?
- No. Compass Pathways’ COMP360 is investigational synthetic psilocybin. COMP005 met its Phase 3 primary endpoint in June 2025 (single 25mg dose vs placebo). COMP006’s 26-week data were announced in July 2026. Compass has discussed a rolling NDA with a possible 2027 launch if FDA approval and DEA rescheduling follow. Until then it is not an approved medicine.
- Is 25mg of COMP360 the same as a mushroom dose in Oregon or Colorado?
- No. 25mg COMP360 is a fixed, high-purity synthetic capsule used in trials. Oregon and Colorado licensed services use natural mushrooms with individually chosen doses inside a supervised service center. Potency and setting are not interchangeable. Clinical research uses measured milligrams to control that variability.
- Who should not take a clinical psilocybin dose?
- Trial protocols generally exclude people with a personal or family history of psychosis or bipolar disorder. Heart conditions and interactions with certain medications are additional cautions. Marks’s point is that the same plasticity window that can help can also destabilize — which is why screening and a trained container matter.
- Can I take a “brain reboot” psilocybin dose at home for depression?
- Marks’s own close is that this will not be a pill you take home. The model is preparation, a supervised session, and integration. Legal access in the U.S. is still clinical trials or state-licensed centers in Oregon and Colorado. Underground sessions exist and carry more risk and less oversight. This article is not an instruction to self-dose.